China Pharma Holdings Inc

China Pharma Holdings Inc

CPHI · AMEX · Healthcare / Drug Manufacturers - Specialty & Generic

0.52USD-0.04 (-7.13%)

Price History

Full chart

Market Stats

Previous Close0.5599
Open0.56
Day Range0.50 – 0.56
52-Week Range0.50 – 8.10
Volume44.60K
Market Cap31.83M
P/E (TTM)0.00
Forward P/E1.56
EPS-0.43
Dividend Yield0.00%
Beta1.05
50-Day Avg1.16
200-Day Avg0.9224

About

China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMs. Zhilin Li
  • Employees215
  • HeadquartersNo. 17, Jinpan Road, Haikou, China, 570216, USA
  • Websitehttps://www.chinapharmaholdings.com

Leadership

  • Ms. Zhilin LiPresident, CEO, Chairman & Interim CFO · b. 1953
  • Ms. Huang Na C.F.A.BOD Secretary & IR Manager

Financials

Income Statement

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue37.49K37.49K110.08K23.27K23.27K21.84M33.19M50.97M61.70M74.39M81.17M54.51M32.81M22.13M20.35M15.57M13.21M12.33M10.92M10.87M9.64M8.10M7.01M4.53M4.14M
Growth (%)-0.00%+193.62%-78.86%0.00%+93748.60%+51.93%+53.58%+21.05%+20.57%+9.11%-32.85%-39.81%-32.53%-8.05%-23.49%-15.15%-6.67%-11.41%-0.53%-11.27%-15.95%-13.48%-35.41%-8.49%
Cost of Revenue--47.68K47.68K47.68K11.75M17.62M25.68M36.05M44.11M52.18M40.43M29.59M19.47M18.89M12.35M10.74M10.36M9.44M8.91M9.29M8.60M7.29M6.51M4.28M
Gross Profit37.49K37.49K110.08K-24.41K-24.41K10.10M15.57M25.29M25.65M30.28M28.99M14.08M3.22M2.67M1.46M3.22M2.47M1.97M1.48M1.95M349.27K-493.92K-281.08K-1.99M-131.95K
Gross Margin100.00%100.00%100.00%-104.86%-104.86%46.23%46.91%49.62%41.57%40.71%35.71%25.82%9.81%12.05%7.20%20.67%18.68%16.02%13.57%17.97%3.62%-6.09%-4.01%-43.84%-3.18%
Operating Expense752.32K752.32K265.72K92.96K92.96K1.47M3.32M5.56M3.04M5.62M6.96M7.58M18.13M39.21M15.66M7.41M6.96M5.94M4.87M4.53M3.21M3.06M2.47M2.60M2.96M
Operating Income-714.83K-714.83K-155.64K-117.37K-117.37K8.62M12.25M19.73M22.61M24.66M22.03M6.50M-14.91M-36.55M-14.20M-4.19M-4.50M-3.97M-3.39M-2.58M-2.86M-3.55M-2.75M-4.59M-3.09M
Operating Margin-1906.73%-1906.73%-141.39%-504.27%-504.27%39.48%36.92%38.71%36.65%33.16%27.14%11.92%-45.44%-165.11%-69.75%-26.93%-34.03%-32.18%-31.03%-23.73%-29.67%-43.79%-39.25%-101.32%-74.53%
EBITDA-970.97K-383.44K386.82K768.15K768.15K9.02M12.06M20.39M24.02M27.77M24.14M7.37M-16.99M-36.90M-10.58M-4.95M-15.32M-7.15M-17.45M106.85K230.34K-837.69K8.44K-1.96M-1.51M
EBITDA Margin-2589.95%-1022.79%351.40%3300.32%3300.32%41.30%36.35%40.01%38.93%37.34%29.74%13.53%-51.77%-166.72%-51.99%-31.77%-115.98%-57.99%-159.75%0.98%2.39%-10.34%0.12%-43.37%-36.35%
Net Income-1.10M-1.10M-226.37K-504.29K-504.29K8.59M12.82M17.83M20.23M23.41M19.27M4.62M-20.01M-26.05M-15.41M-9.18M-19.28M-10.75M-20.70M-2.87M-3.40M-3.97M-3.08M-4.74M-3.19M
Net Income Margin-2945.14%-2945.14%-205.64%-2166.67%-2166.67%39.31%38.63%34.99%32.79%31.48%23.74%8.47%-60.99%-117.68%-75.70%-58.97%-145.91%-87.18%-189.51%-26.38%-35.26%-49.02%-43.91%-104.58%-76.91%
R&D------853.00K---0438.66K1.68M2.80M961.90K365.97K90.47K172.38K229.64K377.96K318.96K185.86K240.08K283.94K280.90K
R&D as % of Total Revenue------2.57%---0.00%0.80%5.13%12.64%4.73%2.35%0.68%1.40%2.10%3.48%3.31%2.29%3.42%6.27%6.78%
Interest Expense49.85K49.85K5.59K5.59K5.59K145.88K237.40K131.03K154.18K168.26K255.20K308.38K348.70K785.80K1.17M849.56K539.33K451.26K321.72K294.16K542.00K434.62K333.60K154.14K102.04K
Interest Expense % of Total Revenue132.98%132.98%5.08%24.04%24.04%0.67%0.72%0.26%0.25%0.23%0.31%0.57%1.06%3.55%5.73%5.46%4.08%3.66%2.95%2.71%5.62%5.36%4.76%3.40%2.46%

Balance Sheet

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets425.67K425.67K298.63K848428.51M43.71M75.47M100.94M131.75M156.39M163.24M157.61M132.08M97.22M78.52M59.95M45.38M22.24M21.12M22.65M17.78M16.47M14.89M31.00M
Total Liabilities992.02K992.02K1.03M68.41K68.41K7.66M3.94M5.60M10.54M13.81M13.91M14.72M24.67M25.83M24.58M19.61M16.88M15.18M13.00M13.11M16.63M13.49M9.01M7.14M8.26M
Total Equity-566.35K-566.35K-733.96K-68.32K-68.32K20.85M39.76M69.87M90.40M117.94M142.48M148.52M132.94M106.25M72.64M58.91M43.07M30.20M9.24M8.00M6.02M4.29M7.45M7.75M22.74M
Cash1.25K1.25K1.79K8484656.44K1.83M6.93M3.63M3.69M4.05M4.03M5.99M5.30M6.25M2.67M2.03M1.19M1.07M957.65K4.86M2.03M1.42M626.88K345.11K
Total Debt499.62K499.62K765.52K-30.97K6.53M2.69M2.48M3.80M3.78M3.93M4.76M17.39M17.92M16.95M11.17M9.93M7.82M6.62M7.43M12.49M8.76M4.63M3.59M3.89M
Net Debt498.37K498.37K763.73K-84-845.88M863.09K-4.45M167.97K89.03K-119.11K731.37K11.40M12.62M10.70M8.50M7.90M6.63M5.55M6.47M7.63M6.73M3.21M2.96M3.54M

Cash Flow

Currency: USD2001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-299.20K-299.20K-93.13K-35.81K-35.81K-1.74M2.80M6.54M10.67M7.79M5.24M3.64M8.60M4.57M3.35M2.90M841.22K1.26M608.31K-42.26K-249.84K-409.55K-699.69K-466.36K148.26K
Investing Cash Flow--250.00K32.58K2.50K2.50K-192.00K--10.44M-15.36M-10.52M-5.63M-4.99M-19.09M-5.84M-1.90M-193.40K-136.48K-51.15K-136.00K-867.31K-438.06K-401.96K-11.52K-291.72K-137.25K
Financing Cash Flow537.78K537.78K61.09K31.61K31.61K2.11M-203.02K8.88M1.39M2.66M595.67K1.29M12.32M605.00K-6.02M-6.02M-1.48M-1.98M-1.73M624.18K4.60M-1.77M73.14K27.35K-294.03K
Capital Expenditure0000484.13K192.00K2.99M8.49M15.36M10.52M5.54M4.99M19.09M5.84M2.32M193.40K136.48K51.15K136.00K867.31K438.06K401.96K11.52K291.72K137.25K
Free Cash Flow-299.20K-299.20K-93.13K-35.81K-35.81K-1.93M-187.37K-1.95M-4.69M-2.73M-306.42K-1.34M-10.50M-1.27M1.03M2.70M704.74K1.21M472.31K-909.57K-687.89K-811.51K-711.20K-758.08K11.01K
Dividends Paid----237.60K237.60K----00000000-------
FCF to OCF100.00%100.00%100.00%100.00%100.00%111.06%-6.69%-29.82%-43.98%-35.10%-5.85%-36.88%-122.12%-27.80%30.77%93.32%83.78%95.93%77.64%2152.31%275.34%198.15%101.65%162.55%7.43%
Dividend Paid to FCF-----663.46%-12.32%----0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%-------

Earnings

Report DateJun 30, 2002Sep 30, 2002Dec 31, 2002Mar 31, 2003Jun 30, 2003Sep 30, 2003Dec 31, 2003Mar 31, 2004Jun 30, 2004Sep 30, 2004Dec 31, 2004Mar 31, 2005Jun 30, 2005Mar 31, 2006Jun 30, 2006Nov 14, 2006Dec 31, 2006May 15, 2007Aug 14, 2007Nov 15, 2007May 2, 2008Aug 6, 2008Nov 7, 2008Mar 17, 2009May 15, 2009Aug 11, 2009Nov 11, 2009Mar 5, 2010May 10, 2010Aug 9, 2010Nov 11, 2010Mar 3, 2011May 11, 2011Aug 11, 2011Nov 10, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Nov 15, 2013Mar 10, 2014Jun 30, 2014Sep 30, 2014Nov 14, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Nov 17, 2015Mar 29, 2016Jun 30, 2016Aug 12, 2016Nov 15, 2016Mar 31, 2017May 12, 2017Aug 15, 2017Nov 15, 2017Mar 31, 2018Apr 3, 2018Aug 15, 2018Nov 15, 2018Mar 31, 2019Apr 2, 2019Aug 15, 2019Nov 15, 2019Feb 26, 2020May 15, 2020Aug 14, 2020Nov 13, 2020Mar 26, 2021May 14, 2021Aug 13, 2021Nov 12, 2021Mar 31, 2022May 19, 2022Aug 18, 2022Nov 18, 2022Mar 31, 2023May 18, 2023Aug 17, 2023Nov 17, 2023Feb 28, 2024May 16, 2024Aug 12, 2024Nov 18, 2024Mar 31, 2025May 14, 2025Aug 14, 2025Nov 12, 2025Aug 14, 2026Nov 11, 2026
EPS Estimate---------------0.50-----1.1045.001.1065.0050.0085.001.3555.0055.0063.3378.331.1555.0060.00------------0.00---0.00---0.00---0.00---0.00-----------0.00--0.000.000.00--------0.000.00--
EPS Actual-837.750.40-160.39-126.30-17.88-442.94-0.472.92-80.00-8.94-14.46-29.73-1045.0025.0026.360.5050.0932.6744.6741.4356.211.0050.001.3045.0050.0085.001.2050.0055.0065.0095.001.2055.3540.000.060.040.03-0.03-0.06-0.10-0.050.080.08-0.20-0.150.080.08-0.090.070.080.08-0.060.080.08-0.02-0.02-0.05-0.05-0.01-0.32-0.02-0.04-0.01-0.17-0.02-0.02-0.43-0.02-0.02-0.02-0.03-0.02-0.02-0.02-0.02-0.02-0.02-0.02-0.20-0.06-2.99-2.94-1.16-0.73-0.89-0.65-0.53-0.24-0.16-0.17-0.04-
Surprise---------------0.00%------9.09%11.11%18.18%-30.77%0.00%0.00%-11.11%-9.09%0.00%2.64%21.28%4.35%0.64%-33.33%----------------------------------------------------------
Timing----------------------Pre-market-Pre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hours--------------------Pre-market-------------------------------------

Key Statistics & Ratios

Market Cap31.83M
Enterprise Value34.73M
Trailing P/E0.00
Forward P/E1.56
PEG Ratio0.16
Price / Sales8.13
Price / Book0.86
EPS-0.43
Book Value0.893
Revenue (TTM)3.91M
Gross Profit (TTM)460.17K
EBITDA-1.44M
Profit Margin-114.33%
Operating Margin-150.98%
Return on Equity-20.99%
Return on Assets-9.36%
Shares Outstanding43.02M
Shares Float3.30M
Beta1.05
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 15, 20251:10
  • Mar 6, 20241:5
  • Mar 6, 20231:10
  • Aug 15, 20031000:21804